Table 1.
Pharmacological molecules | Patient numbers | Proportion within each drug class % |
---|---|---|
Anti-platelet agents (n = 2031) | ||
Aspirin alone | 234 | 11.5 |
Aspirin–clopidogrel | 1797 | 88.4 |
β-Blockers (n = 1494) | ||
Atenolol | 566 | 37.8 |
Metoprolol | 394 | 26.4 |
Carvedilol | 178 | 11.9 |
Bisoprolol | 139 | 9.3 |
Nebivolol | 108 | 7.2 |
Propanolol | 74 | 4.9 |
Others | 35 | 2.3 |
Angiotensin converting enzyme inhibitors (n = 1196) | ||
Ramipril | 504 | 42.1 |
Lisinopril | 243 | 20.3 |
Perindopril | 131 | 10.9 |
Enalapril | 147 | 12.3 |
Captopril | 87 | 7.3 |
Trandolapril | 54 | 4.5 |
Others | 30 | 2.5 |
Angiotensin receptor blockers (n = 712) | ||
Losartan | 340 | 47.7 |
Valsartan | 159 | 22.3 |
Telmisartan | 106 | 14.9 |
Candesartan | 70 | 9.8 |
Others | 37 | 5.2 |
Calcium channel blockers (n = 1023) | ||
Amlodipine | 485 | 47.5 |
Diltiazem | 298 | 29.1 |
Verapamil | 97 | 9.5 |
Nifedipine | 46 | 4.5 |
Felodipine | 47 | 4.6 |
Nicardipine | 23 | 2.2 |
Others | 27 | 2.6 |
Statins (n = 1457) | ||
Atorvastatin | 726 | 49.8 |
Simvastatin | 422 | 28.9 |
Rosuvastatin | 267 | 18.3 |
Others | 42 | 2.8 |
Other lipid lowering (n = 170) | ||
Fibrates | 71 | 41.7 |
Niacin | 29 | 17.0 |
Orlistat | 35 | 20.6 |
Others | 35 | 20.6 |